Alector Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
241
- Stock Symbol
-
ALEC
- Share Price
-
$5.75
- (As of Friday Closing)
Alector General Information
Description
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Contact Information
Website
www.alector.comCorporate Office
- 151 Oyster Point Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 151 Oyster Point Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Alector Stock Performance
As of 08-Nov-2024, Alector’s stock price is $5.75. Its current market cap is $563M with 97.9M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.75 | $5.64 | $3.66 - $8.90 | $563M | 97.9M | 527K | -$1.71 |
Alector Financials Summary
As of 30-Sep-2024, Alector has a trailing 12-month revenue of $61.5M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (13,705) | 122,780 | 49,474 | 949,122 |
Revenue | 61,508 | 97,062 | 133,617 | 207,085 |
EBITDA | (147,642) | (116,331) | (121,584) | (28,014) |
Net Income | (158,409) | (130,391) | (133,310) | (36,329) |
Total Assets | 516,023 | 621,827 | 787,648 | 814,658 |
Total Debt | 34,639 | 38,918 | 43,327 | 47,601 |
Alector Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Alector Comparisons
Industry
Financing
Details
Alector Competitors (72)
One of Alector’s 72 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
PAQ Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Alector Patents
Alector Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023225020-A1 | Methods of use of anti-trem2 antibodies | Pending | 23-Feb-2022 | ||
US-20240329054-A1 | Soluble cd33 as a biomarker for anti-cd33 efficacy | Pending | 08-Nov-2021 | ||
EP-4419558-A1 | Anti-cd300lb antibodies and methods of use thereof | Pending | 19-Oct-2021 | ||
US-20240254227-A1 | Anti-cd300lb antibodies and methods of use thereof | Pending | 19-Oct-2021 | ||
EP-4392448-A2 | Pilra antibodies and methods of use thereof | Pending | 25-Aug-2021 | C07K16/2803 |
Alector Signals
Alector Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Alector ESG
Risk Overview
Risk Rating
Updated February, 01, 2024
27.33 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,035
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Alector FAQs
-
When was Alector founded?
Alector was founded in 2013.
-
Where is Alector headquartered?
Alector is headquartered in South San Francisco, CA.
-
What is the size of Alector?
Alector has 241 total employees.
-
What industry is Alector in?
Alector’s primary industry is Drug Discovery.
-
Is Alector a private or public company?
Alector is a Public company.
-
What is Alector’s stock symbol?
The ticker symbol for Alector is ALEC.
-
What is the current stock price of Alector?
As of 08-Nov-2024 the stock price of Alector is $5.75.
-
What is the current market cap of Alector?
The current market capitalization of Alector is $563M.
-
What is Alector’s current revenue?
The trailing twelve month revenue for Alector is $61.5M.
-
Who are Alector’s competitors?
Cognition Therapeutics, Lexeo Therapeutics, PAQ Therapeutics, Orchard Therapeutics, and CRISPR Therapeutics are some of the 72 competitors of Alector.
-
What is Alector’s annual earnings per share (EPS)?
Alector’s EPS for 12 months was -$1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »